author-photo

Stanford Peng

Seattle Genetics

6

Papers

34

Citations

Citation Trend

Filter By

Papers (3) Sort By

Journal Conference Others

OA05.03 Single-Agent Rovalpituzumab Tesirine, a Delta-Like Protein 3 (DLL3)-Targeted Antibody-Drug Conjugate (ADC), in Small-Cell Lung Cancer (SCLC)

2017 Journal of Thoracic Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Metastatic melanoma, glioblastoma and high-grade extrapulmonary neuroendocrine carcinomas (NECs) as novel indications for rovalpituzumab tesirine: A delta-like protein 3 (DLL3)-targeted antibody-drug conjugate (ADC).

2016 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Abstract 2472: SEA-CD40, a sugar engineered non-fucosylated anti-CD40 antibody with improved immune activating capabilities

2015 Cancer Research
Show All
- Source
- Cite
- Save
Citations (5)